[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589461":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":163,"collaborators":166,"id":170,"slug":171,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":172,"sex":177,"minAge":178,"maxAge":26,"enrollmentInfo":179,"targetDuration":26,"studyType":182,"phases":183,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":80,"whyStopped":26,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},{"fullName":5,"class":6},"Chonnam National University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Drug-eluting stent","ACTIVE_COMPARATOR","In DES group, latest second-generation DES will be used in accordance with standard practice guideline.",[13],"Procedure: Drug-eluting stent implantation",{"label":15,"type":16,"description":17,"interventionNames":18},"Drug-coated balloon","EXPERIMENTAL","In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds.",[19],"Procedure: Drug-coated balloon angioplasty",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Drug-eluting stent implantation","IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \\>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups.\n\nIn DES group, latest second-generation DES will be used in accordance with standard practice guideline.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Drug-coated balloon angioplasty","IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \\>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups.\n\nIn DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds.",[15],[32],{"name":33,"affiliation":34,"role":35},"Young Joon Hong, MD, PhD","Chonnam National University","STUDY_CHAIR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Seung Hun Lee, MD, PhD","CONTACT","+82-62-220-6246","lsh8602@naver.com",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":45},"Joon Ho Ahn, MD, PhD","+82-62-220-5778","yhbky@naver.com",[47,65,79,96,109,127,138,149],{"facility":48,"status":49,"city":50,"state":50,"zip":51,"country":52,"countryCode":26,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Kosin University Gospel Hospital","NOT_YET_RECRUITING","Busan","49269","South Korea",{"type":54,"coordinates":55},"Point",[56,57],129.03004,35.10168,{"lat":57,"lon":56},[60,63],{"name":61,"role":39,"phone":26,"phoneExt":26,"email":62},"Jung Ho Heo, MD, PhD","duggymdc@gmail.com",{"name":61,"role":64,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"facility":66,"status":49,"city":67,"state":67,"zip":68,"country":52,"countryCode":26,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Keimyung University Dongsan Hospital","Daegu","42601",{"type":54,"coordinates":70},[71,72],128.59111,35.87028,{"lat":72,"lon":71},[75,78],{"name":76,"role":39,"phone":26,"phoneExt":26,"email":77},"Hyuck-Jun Yoon, MD, PhD","hippsons@gmail.com",{"name":76,"role":64,"phone":26,"phoneExt":26,"email":26},{"facility":34,"status":80,"city":81,"state":81,"zip":82,"country":52,"countryCode":26,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"RECRUITING","Gwangju","61469",{"type":54,"coordinates":84},[85,86],126.91556,35.15472,{"lat":86,"lon":85},[89,91,92,93,95],{"name":33,"role":39,"phone":26,"phoneExt":26,"email":90},"hyj200@hanmail.net",{"name":38,"role":39,"phone":26,"phoneExt":26,"email":41},{"name":33,"role":64,"phone":26,"phoneExt":26,"email":26},{"name":38,"role":94,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"name":43,"role":94,"phone":26,"phoneExt":26,"email":26},{"facility":97,"status":49,"city":98,"state":98,"zip":99,"country":52,"countryCode":26,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Jeonbuk National University Hospital","Jeonju","54907",{"type":54,"coordinates":101},[102,103],127.14889,35.82194,{"lat":103,"lon":102},[106,108],{"name":107,"role":39,"phone":26,"phoneExt":26,"email":26},"Yi Sik Kim, MD, PhD",{"name":107,"role":64,"phone":26,"phoneExt":26,"email":26},{"facility":110,"status":49,"city":111,"state":111,"zip":112,"country":52,"countryCode":26,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Samsung Medical Center","Seoul","06351",{"type":54,"coordinates":114},[115,116],126.9784,37.566,{"lat":116,"lon":115},[119,122,123,125],{"name":120,"role":39,"phone":26,"phoneExt":26,"email":121},"Joo Myung Lee, MD, PhD","drone80@hanmail.net",{"name":120,"role":64,"phone":26,"phoneExt":26,"email":26},{"name":124,"role":94,"phone":26,"phoneExt":26,"email":26},"Ki Hong Choi, MD, PhD",{"name":126,"role":94,"phone":26,"phoneExt":26,"email":26},"Young Bin Song, MD, PhD",{"facility":128,"status":49,"city":111,"state":111,"zip":129,"country":52,"countryCode":26,"cosmosGeoPoint":130,"geoPoint":132,"contacts":133},"Ewha Womans University Mokdong Hospital","07985",{"type":54,"coordinates":131},[115,116],{"lat":116,"lon":115},[134,137],{"name":135,"role":39,"phone":26,"phoneExt":26,"email":136},"Sodam Jung, MD, PhD","cvdosam@gmail.com",{"name":135,"role":64,"phone":26,"phoneExt":26,"email":26},{"facility":139,"status":49,"city":111,"state":111,"zip":140,"country":52,"countryCode":26,"cosmosGeoPoint":141,"geoPoint":143,"contacts":144},"Korea University Guro Hospital","08308",{"type":54,"coordinates":142},[115,116],{"lat":116,"lon":115},[145,148],{"name":146,"role":39,"phone":26,"phoneExt":26,"email":147},"Dong Oh Kang, MD, PhD","gelly9@naver.com",{"name":146,"role":64,"phone":26,"phoneExt":26,"email":26},{"facility":150,"status":49,"city":151,"state":151,"zip":152,"country":52,"countryCode":26,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Ulsan University Hospital","Ulsan","44033",{"type":54,"coordinates":154},[155,156],129.31667,35.53722,{"lat":156,"lon":155},[159,162],{"name":160,"role":39,"phone":26,"phoneExt":26,"email":161},"Eun Seok Shin, MD, PhD","sesim1989@gmail.com",{"name":160,"role":64,"phone":26,"phoneExt":26,"email":26},{"type":64,"investigatorFullName":164,"investigatorTitle":165,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Young Joon Hong","Professor",[167],{"name":168,"class":169},"Boston Scientific Corporation","INDUSTRY","100589461","late-lumen-changes-after-drug-coated-balloon-angioplasty-versus-drug-eluting-stents-in-de-novo-coronary-lesions-100589461",false,"NCT06954714","Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions","LARGER-DCB","Inclusion Criteria\n\n1. Subject must be at least 19 years of age\n2. Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily\n3. Patients with at least one lesion with greater than 50% diameter stenosis or fractional flow reserve ≤0.80 requiring revascularization in de-novo coronary artery of reference vessel size ≥3.0 mm\n\nExclusion Criteria\n\n1. Patients unable to provide consent\n2. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents\n3. Patients with angiographic findings of 1) Left main coronary artery disease 2) In-stent restenosis is the cause of target lesion 3) Target lesion in bypass graft 4) True bifurcation lesion that requires upfront 2-stenting\n4. Patients who have non-cardiac co-morbid conditions with life expectancy \\\u003C1 year\n5. Patients who may result in protocol non-compliance (site investigator's medical judgment)\n6. Patients with cardiogenic shock or cardiac arrest\n7. Patients with severe left ventricular systolic dysfunction (ejection fraction \\\u003C30%)\n8. Patients with severe valvular heart disease requiring open heart surgery\n9. Pregnant or lactating women","ALL","19 Years",{"count":180,"type":181},256,"ESTIMATED","INTERVENTIONAL",[184],"NA","This study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).",[187],"Coronary Artery Disease",[189,190],"drug-coated balloon","intravascular ultrasound","2026-05-08",{"date":193,"type":194},"2026-05-12","ACTUAL",{"date":196,"type":194},"2025-08-18",{"date":198,"type":181},"2028-12-31",{"name":5,"class":6},8]